Skip to main content

T3D-959 Alzheimer's Disease Proof of Concept Studies

Printer-friendly versionPrinter-friendly versionSend by emailSend by email
Award date: 
May 13, 2014
Award amount: 
$250,000
Organization name: 
T3D Therapeutics, Inc.
Principal Investigator: 
Didsbury, John
Grant program category: 
Business Financing
Grant program name: 
Small Business Research Loan
Region: 
Research Triangle

T3D-959 is a Phase 1-completed, oral, once-a-day drug being developed for the treatment of cognitive and functional decline in Alzheimer's disease. The studies to be carried out in this project are aimed at demonstrating both pre-clinically and clinically the drug's therapeutic utility to be a disease remedial therapeutic.

Fiscal year: 
2014